| 摘要 |
FIELD: medicine.SUBSTANCE: invention relates to medicine,namely to ophthalmology, and aims at treating occlusions of central vein of retina (OCVR) and its branches (OBCVR). Intravitreal introduction of implant Ozurdeks® is made. At reduction of therapeutic effect in period from 3 to 6 months after beginning of treatment introduction of implant Ozurdeksis repeated. After 2 weeks laser retinal coagulation in area of edema is made with Nd:YAG laser at wave length of 561 nm, pulse duration 10 ms, power from 70 to 160 mW. At occlusion of central vein of retina 500-2,500 coagulation applications with diameter of 50-300 mcm are applied to edema area with distance between them of 50-450 mcm. In presence of occlusion of temporal branch of central vein of retina 500-1,000 coagulation applications with diameter of 50-300 mcm are applied to edema area with distance between them of 50-450 mcm. In presence of occlusion of macular temporal branches of central vein of retina 100-300 coagulation applications with diameter of 50 mcm are applied to edema area with distance between them of 50-75 mcm. In presence of third-order veins' occlusion 300-1,000 coagulation applications with diameter of 100-300 mcm are applied to edema area with distance between them of 100-450 mcm.EFFECT: method is simple, minimally invasive, allows to achieve controlled and stable therapeutic effect of intravitreal implant Ozurdeksin short period of time with no side effects and postoperative complications; if necessary, method can be used repeatedly, since no inflammatory and cicatrical-sclerotic changes of retinal tissue are observed as result of conducted therapy.5 cl, 8 dwg, 4 ex |
